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Introduction
Intravitreal (IVT) corticosteroids are routinely used in the treatment of sight threatening conditions in the back of the eye including diabetic macular edema (DME), proliferative vitreoretinopathy, endophthalmitis and uveitis. Administration by IVT injection allows the steroids to bypass the blood-retinal barrier (BRB), leading to higher drug concentrations close to the site of action in the posterior cavity. 1 Common corticosteroids used to treat ophthalmic conditions include dexamethasone, triamcinolone acetonide (TA) and fluocinolone acetonide (FA). Unfortunately, low molecular weight, permeable molecules including corticosteroids that are dissolved in the vitreous rapidly clear from the eye displaying a relatively short t 1/2 that is of a matter of hours (i.e. 3-7 hours). [2] [3] [4] [5] Frequent IVT injections to maintain therapeutic drug concentrations can increase the risk of serious adverse reactions including retinal detachment, endophthalmitis and vitreous hemorrhage. 6 Steroid suspensions have long been used clinically in an effort to reduce the number of IVT injections. Triamcinolone acetonide (TA) is available as a preservative-free injectable suspension for intraocular use (Triesence ® , Alcon).
Kenalog ® is a TA injectable suspension that is indicated for intramuscular and intraarticular administration; and has been used off-label for many years [7] [8] [9] for treating both anterior and posterior segment ocular diseases. To further increase the duration of action, long-acting corticosteroid implants 10 are now clinically available. 3, [10] [11] [12] [13] [14] [15] Corticosteroids 16 are potent, anti-inflammatory agents that are generally stable, poorly soluble and slowly dissolving and so are ideal drug substances for use in longer acting dosage forms. The volume of the vitreous cavity is approximately 4.2 mL, so non-sink conditions can be exploited to prolong the release kinetics of IVT implants of corticosteroids. Ozurdex ® (Allergan, Inc) is a poly(lactic-co-glycolic acid) (PLGA) implant, which releases dexamethasone (0.7 mg) over a 6-month period. 17 Formulating a corticosteroid in a PLGA matrix allows better control of drug release compared to the dissolution of a free drug suspension. Interestingly, Ozurdex ® displays a similar PK profile between vitrectomised and non-vitrectomised eyes 18 whereas suspensions of TA clear more quickly in vitrectomised eyes. 19 However, Ozurdex ® is a single depot plug, so there is limited flexibility in reducing the duration of action to less than 6-months. Thus, in an effort to exploit the controlled release properties of PLGA for IVT administered dexamethasone with the possibility of varying the dose and duration of action, we describe the preparation of dexamethasone-PLGA microparticles prepared by thermally induced phase separation (TIPS). 20 TIPS has been used to fabricate porous drug vehicles for applications in chronic wound therapy, drug delivery and tissue engineering. 21 The technique used to produce TIPS microsparticles is rapid and provides high encapsulation efficiency generating spherical particles with rigid outer surfaces and longer shelf-life. 22 The encapsulation yield for microparticles containing particulate infliximab was 60.4 ± 5.9% compared with 37.9 ± 14.4% for microspheres containing an emulsion of infliximab. 21 Degradable polymeric microparticles can enable a prolonged therapeutic concentration to be available while the porous particle surface aids resorption and reduces the likelihood of autocatalysis associated with solid microparticles. PLGA depots are biodegradable which avoids the need for surgical removal from the eye after drug depletion. 23 Porous PLGA microparticles are ideal for drug delivery because the amount of polymer per microparticle is reduced compared with solid microparticles of an equal size.
A two-compartment in vitro model of the eye, known as the PK-Eye that predicts human clearance times caused by the aqueous outflow pathway 24 was used to determine drug release kinetics of the dexamethasone TIPS microparticles.
Aqueous outflow (2.0 to 2.5 μL/min) [25] [26] [27] [28] [29] is the main cause of mass transfer within the eye. The aqueous nourishes the avascular lens and cornea with outflow passing through the front of the eye. The PK-Eye provides a good estimate of human clearance times from the vitreous cavity for protein therapeutics and non-permeable low molecular weight molecules from suspension and depots. 24 Permeable low molecular weight molecules are eliminated from the vitreous cavity by both aqueous outflow and permeation through the retina via the retinal-choroid-sclera (RCS)
pathways. Utilising the PK-Eye to estimate the clearance of low molecular weight, retinal permeable compounds such as steroids requires that we combine in vitro outflow clearance data from the PK-Eye, published drug permeability and in vivo human data, when available, to develop in vitro in vivo correlations (IVIVC). The goal of the work described herein was also to develop IVIVC methodology, which can be used as a surrogate for in vivo ocular pharmacokinetic studies during preclinical optimisation to develop sustained release ocular preparations.
Experimental

Materials and instrumentation
Sodium hyaluronate (solubility: 5.0 mg/mL; 1. 
Preparation of the PK-Eye for in vitro studies
Design of the model
The design and use of the in vitro PK-Eye model has been previously reported. 24 Briefly, the PK-Eye is fabricated from plastic (polyacrylate) with anterior (~0. 
Preparation of simulated vitreous
Agar (0.4 g) and hyaluronic acid (HA) (0.5 g) were each separately mixed in 100 mL of stirred hot water. 30 The agar solution was boiled to completely solubilise the agar.
After boiling, the hot agar solution was mixed with HA and stirred to give a homogenous mixture to which a few drops of 0.02% sodium azide were added. The 
Preparation of dexamethasone-PLGA TIPS microparticles
PLGA TIPS microparticles were prepared as previously described. 21 
Characterisation of TIPS microparticles
Scanning electron microscopy (SEM)
TIPS microparticles were mounted onto aluminium stubs via adhesive carbon tabs, sputter coated with 1-2 nm of gold/palladium alloy for 3 minutes in an argon atmosphere using a high resolution ion beam coater (Gatan Model 681) and viewed by SEM.
Encapsulation and in vitro drug release studies with the PK-Eye
Equivalent amounts of dexamethasone loaded TIPS microparticles were transferred to 1.0 mL syringes and pressure was applied to the syringe to pack the particles. To obtain dexamethasone loading, the dried, packed dexamethasone TIPS microparticles in 0.05 mL volume were then transferred to a glass vial containing DMSO (2.5 mL) and vortexed until completely dissolved. The solution was then diluted 10 times in PBS, pH 7.4. The mixture was sonicated for 15 minutes and the resulting solution was filtered using a 0.22 µm filter. Dexamethasone concentration was determined with HPLC (240 nm).
The PK-Eye models were assembled using a fresh Visking membrane for each model. The posterior cavity of the model was filled with the appropriate vitreous substitute (PBS, pH 7.4 or simulated vitreous) and the anterior cavity of the model was filled with PBS. Negative controls were conducted with PK-Eye models with the vitreous substitutes containing no particles.
Dexamethasone is poorly water soluble (0.1 mg/mL), so a dexamethasone suspension was prepared in water (0.2 mg / 50 µL) to enable direct comparison of the clearance profiles of the suspension and TIPS preparations. Dexamethasone suspension and dry PLGA TIPS microparticles were injected into the posterior cavity of the PK-Eye model. The aqueous outflow was collected from the anterior cavity and was used to determine drug concentrations at different time points. Each sample was filtered using a 0.22 μm filter before HPLC analysis.
Dexamethasone quantification by high performance liquid chromatography (HPLC-UV)
A wavelength of 240 nm was used to detect dexamethasone. The mobile phase The calibration curve (R 2 value of 0.998) was prepared with dexamethasone in PBS, pH 7.4 with a concentration range of 0.39 μg/mL to 100 μg/mL.
Establishing in vitro-in vivo correlations (IVIVC)
Use of the PK-Eye model to predict the in vivo drug clearance from the posterior compartment was performed with suspensions of two model drugs; triamcinolone acetonide (TA) (solubility 25 μg/mL) 24 and dexamethasone (0.1 mg/mL). TA (4.0 mg) displayed constant concentrations (21-30 μg/mL) in the posterior cavity of the PKEye model. 24 In vivo drug clearance data from the posterior compartment was obtained from published values obtained from humans. 19 The PK-Eye overestimates the in vivo clearance times of small molecular weight drugs due to the lack of the RCS pathway in the model. Therefore, drug permeation data across the RCS pathway was used with anterior aqueous outflow clearance time from the PK-Eye to predict in vivo drug clearance. Details are provided in results and discussion.
Data analysis
All data reported were conducted in triplicate (n=3) and results are presented as the mean and standard deviation (±STD). The data obtained were plotted using 
Results and Discussion
Characterisation of TIPS microparticles
Scanning electron microscopy (SEM)
Spherical dexamethasone-loaded TIPS microparticles were observed within the sieved size range of 250-425 μm. The surface of the microparticles was smooth, peppered with pores that were generally distributed in chevron-like patterns created by the freezing of the DMC solvent during fabrication process. 32 The pore size at the surface of the microparticles was approximately 0.2 -1.0 μm. A large pore was visible on the surface of some of the microparticles, which is a typical feature of TIPS microparticles. 32 At higher magnification, amorphous features embedded in the polymer were evenly distributed across the surface of the microparticles, which were likely to consist of dexamethasone since they were not present in unloaded control microparticles.
Figure 1
Encapsulation and in vitro drug release studies with the PK-Eye
The loading efficiency of the dexamethasone loaded TIPs microparticles was determined prior to evaluation in the PK-Eye. Approximately 0.20 ± 0.02 mg of dexamethasone was present in a volume of 50 μL packed dexamethasone TIPS microparticles following the method listed on section 2.4.2 ( Figure S1 ). The dexamethasone TIPS microparticles were injected into the posterior cavity of the PKEye ( Figure S2 ) using a 1.0 mL syringe fitted with a 23G needle.
Figures S1-2
Dry dexamethasone TIPS microparticle formulations and dexamethasone suspension (control) were injected at an equivalent dose (0.2 mg) into the posterior cavity of the PK-Eye containing simulated vitreous at 37°C (Table 1 and Figure 2 ).
The dexamethasone collected from the model outflow was quantified by HPLC (240 nm UV ansorbance). Dexamethasone TIPS microparticles (0.2 mg) showed a t 1/2 of 9.6 ± 0.3 days in simulated vitreous (Figure 2A ). The C max and lowest concentration of solubilised dexamethasone detected were 9.3 ± 0.1 μg/mL (21 hours) and 1.0 ± 0.1 μg/mL (425 hours) respectively. After 160 hours, a nearly constant concentration of 1.9 ± 0.7 μg/mL of dexamethasone was present from the outflow of the model. By 500 hours (~3 weeks), 78.8 ± 1.2 % of the dexamethasone dose had been released.
The average amount of solubilised dexamethasone released from the anterior cavity ranged from ~1.0-3.0 μg/mL from weeks 1 to 3.
In contrast, an equivalent dose of dexamethasone suspension almost completely cleared within 100 hours in simulated vitreous ( Figure 2B ) from the PKEye. The dexamethasone C max was 34 μg/mL at 17.6 hours and elimination followed first order kinetics with a t 1/2 of 1.0 ± 0.1 days. Similar drug release kinetics was observed when half the dose of the dexamethasone suspension (0.1 mg, 50 μL) was evaluated in the PK-Eye (t 1/2 : 1.2 ± 0.03 days, Table 1 ).
Table 1 and Figure 2
Dexamethasone-TIPS microparticles (50 μL) were then evaluated in the PKEye using PBS (pH 7.4) in the posterior cavity ( Figure 3 ) and a t 1/2 of 3.1 ± 0.2 days was observed. The C max and the lowest concentration of solubilised dexamethasone detected were 17.7 ± 8.9 μg/mL (~21 hours) and 1.0 ± 0.2 μg/mL (~376 hours)
respectively. Dexamethasone was still releasing slowly under these conditions with ~99.0 ± 0.4% being released in 3 weeks. A higher burst effect was seen with these particles in PBS compared to simulated vitreous.
The release of dexamethasone in PBS was significantly faster than in simulated vitreous. PLGA undergoes degradation through hydrolysis of its ester linkages to lactic and glycolic acid units, and drug release occurs by both diffusion and erosion. A higher viscosity medium could slow drug diffusion after release from the polymer matrix resulting in longer time periods for the drug to become distributed within the vitreous cavity of the PK-Eye. In contrast, the dexamethasone suspension (0.1 mg, 50 μL) displayed a t 1/2 of 1.3 ± 0.1 days in PBS, which was similar to what was observed in simulated vitreous (t 1/2 1.2 ± 0.03 days) ( Table 1) . Simulating the composition of physiological fluids in drug release studies improves the capacity to determine IVIVCs for modified release delivery systems, as has been observed in oral drug delivery, 33 so the choice of simulated vitreous is important for matrix formulations rather than more simple suspensions that simply dissolve. 
Drug clearance in vitro-in vivo correlations (IVIVCs)
In vitro release studies of ocular formulations have traditionally been conducted in water baths with constant agitation, dialysis membranes on a shaker stand or using USP 4 flow-through cell dissolution apparatus. [34] [35] [36] The drawback with these in vitro methods is that they do not mimic the human eye in terms of dimensions, compartmentalisation and aqueous outflow. Ocular aqueous outflow plays a major role in drug clearance. The PK-Eye was designed to specifically mimic the aqueous outflow from the eye which is critical to estimate the clearance of non-permeable molecules such as therapeutic proteins. 24 The PK-Eye model is also thought to be of value for estimating the dissolution rates of suspensions and the release profiles of implants from the vitreous cavity. has long been used clinically, so TA was first used to confirm if the PK-Eye could be used to estimate the human clearance time for a molecule that clears by both the RCS and anterior pathways.
Correlating TA clearance from the PK-Eye to human clearance
Human in vivo elimination t 1/2 of IVT administered TA suspension (4.0 mg) is about 15.6 days (~374 hours), 19 whereas the in vitro t 1/2 clearance from the PK-Eye is 26-28 days. 24 The total amount of TA leaving the posterior cavity through aqueous outflow can be estimated from the total inflow volume circulating through the human eye and drug concentration in posterior cavity. With a flow rate of 2.0 µL/min, the total volume (flow rate × time) circulating through the posterior cavity over one drug t 1/2 (~374 hours; ~15.6 days) 19 is approximately 44.9 mL. Since TA is injected as a suspension, it is always present in excess in the vitreous compartment and exists at a constant, steady concentration of ~25 µg/mL which is equivalent to the saturation solubility of the drug. 24 The amount of drug eliminated from the posterior cavity through only the aqueous outflow over one drug t 1/2 is therefore 1.1 mg (44.9 mL × 25 µg/mL) ( Table 2) .
Table 2
Using the vitreal clearance t 1/2 of TA in humans (~374 hours), we can estimate the amount of TA leaving the posterior compartment through aqueous outflow permeation through the RCS pathway. Since 4.0 mg of TA was IVT injected in vivo, then after one t 1/2 the amount of TA cleared from the posterior segment is 2.0 mg.
The difference between in vivo and in vitro drug elimination after one t 1/2 is 0.878 mg.
Permeability can be determined from Fick's First Law. The concentration gradient across the RCS pathway can be assumed to be constant since sink conditions exist after permeation. The surface area of the RCS was assumed to be equivalent to the surface area of the retinal pigment epithelium (RPE) and taken as 1204 mm 
= Equation 1
where J is drug flux, Q is total drug amount clearing from the vitreous (0.878 mg), SA is surface area of the RCS pathway (1204 mm 2 ), t is t 1/2 (374 hrs), P is drug permeability across the RCS pathway and C is drug concentration in donor compartment (~25 μg/mL).
There is limited data on drug permeability across human RCS. To our knowledge, the only human permeability data available is that for beta-blockers. A study by Kadam et al. (2011) reported the permeability range for eight beta-blockers across the human scleral choroidal retinal pigment epithelium (SCRPE) to be 1.34 × 10 -6 to 6.03 × 10 -6 cm/sec. 39 Our value for TA permeability (2.2 × 10 -6 cm/sec) determined from published human in vivo clearance data and the PK-Eye model falls within this range and is closest to the beta-blockers with similar lipophilicity. Thus by combining in vitro drug clearance data from the PK-Eye model with drug permeability across the RCS pathway, in vivo drug elimination t 1/2 of small molecules existing in excess amounts in the vitreous chamber can be predicted.
Correlating dexamethasone clearance from the PK-Eye to human clearance
In vivo clearance t 1/2 of solubilised dexamethasone from the vitreous in humans is reported to be 5.5 hours. 40 At a 0.2 mg dose, the dexamethasone concentration in the vitreous chamber will be decreasing over time, so the time for the total drug amount (Q) to clear via aqueous outflow was calculated using Equation 2 with a time point of 17.6 hrs from the release studies.
∫
Equation 2
Drug clearance was determined at 17.6 hours since this is the time point closest to dexamethasone in vivo t 1/2 (5.5 hours), for which we have in vitro drug concentrations. Thus at 17.6 hrs, the amount of drug that had cleared the vitreous in vitro, was determined to be 79.5 µg ( Figure 3B ). In vivo, however, the amount of drug cleared from the vitreous compartment after 3 t 1/2 (17.6/ 5.5 hours) at an equivalent injection dose of 200 µg is 175 µg. Therefore, the amount of drug cleared due to permeation across the RCS pathway is 95.5 µg. Again, since the drug concentration in the vitreous compartment is changing with time, Equation 3 was used to determine retinal permeability.
∫
Equation 3
Retinal permeability of dexamethasone was calculated to be 3.3 x 10 -6 cm/sec. A value for RCS permeability of dexamethasone in humans could not be found, however the reported value in porcine is 2.2 x 10 -6 cm/sec. 41 This is in close agreement to the value we calculate using the PK-Eye.
Prediction of in vivo clearance of dexamethasone-TIPS microparticles
Now that we have shown the PK-Eye can provide a good estimate of IVIVCs, we can use the model to predict the clearance t 1/2 of sustained release IVT implants. At 96 hours, the amount of dexamethasone slowly released from the TIPS microparticles and cleared from the PK-Eye by aqueous outflow was determined using Equation 2
to be 68.3 µg (Table 3) . Drug permeation across the RCS pathway was determined using Equation 3 to be 98.1 µg Table 3 Assuming first order elimination, the predicted human clearance t 1/2 of dexamethasone that would be slowly released from the TIPS microparticles was calculated to be 48 hours using Equation 4c (Equation derived from Equations 4a and 4b).
Equation 4a
⁄
Equation 4b
Equation 4c where A 0 is initial amount of drug in vitreous chamber; 200 µg, A t is drug remaining in vitreous chamber (49.7 µg) and t is time (96 hrs).
The predicted t 1/2 of dexamethasone TIPS microparticles (0.2 mg dexamethasone dose) is almost 9 times longer than that of an equivalent dose of dexamethasone suspension. A dexamethasone TIPS microparticle formulation would be expected to require less frequent IVT injection than a dexamethasone suspension. The PK-Eye estimates the human clearance times of protein therapeutics effectively because these charged, large molecular weight drugs are not permeable and clear predominantly via aqueous outflow through the anterior chamber. 24 The development of effective long-acting formulations of proteins is one of the most important issues in ocular drug delivery today. In addition, the ability to accurately titrate duration of action is important as some drugs such as dexamethasone may have significant side effects in the long term such as an intractable rise in intraocular pressure if delivered to the eye for too long a duration.
Quality control efforts can be facilitated and surrogates for bioequivalence studies can be developed for generic drug product approval. Little has been published about drug metabolism in the vitreous cavity, so practical strategies using the PK-Eye to better account for metabolism in the vitreous may need to be developed for some drugs. While estimation of the overall clearance time is important for preclinical development, integration of our results with advanced in silico models to encompass drug distribution, metabolism and permeability across different pathways will add further insight to the fate of drugs from long acting formulations developed for the eye.
Conclusions
In this study, biodegradable dexamethasone loaded PLGA TIPS microparticles were fabricated as a sustained intraocular dexamethasone formulation. Using the PK-Eye 
